Biotest AG / Key word(s): Change in Forecast
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)
Dreieich, 22 January 2013. Biotest AG announces that earnings after tax for
the year 2012 will increase by approx. EUR 10 million. (This additional
income will be reported in earnings after tax from Discontinued Operation.)
This income results from the sale of the former segment Microbiological
Monitoring. At the time of the sale a patent law suit was still pending, in
which heipha Dr. Müller GmbH was accused of infringing a patent of a
plaintiff. The patent claim has now been effectively declared null and void
by the Federal Court of Justice. Thereupon the plaintiff withdraw the
lawsuit against heipha Dr. Müller GmbH. Biotest is entitled to claim the
remaining purchase price from the buyer of the sold business.
The Executive Management Board
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
application of immunology and haematology. In its Plasma Protein portfolio,
Biotest develops and markets immunoglobulins, coagulation factors and
albumins based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. Biotest also researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and cancer of plasma cells. Biotest has more than
1,600 employees worldwide. The preference shares of Biotest AG are listed
in the SDAX on the Frankfurt stock exchange.
Securities´ ID No., ISIN ordinary shares: 522720, DE0005227201
Securities´ ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
22.01.2013 DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Company: Biotest AG
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of Announcement DGAP News-Service